Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
or

Neurocrine Bioscienc (NBIX)

Neurocrine Bioscienc (NBIX)
104.61 x 1 121.28 x 3
Pre-market by (Cboe BZX)
114.45 -1.73 (-1.49%) 03/26/25 [NASDAQ]
104.61 x 1 121.28 x 3
Pre-market 114.45 unch (unch) 16:00 ET
Quote Overview for Wed, Mar 26th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
113.05
Day High
116.23
Open 116.23
Previous Close 116.18 116.18
Volume 974,800 974,800
Avg Vol 1,297,625 1,297,625
Stochastic %K 93.98% 93.98%
Weighted Alpha -20.19 -20.19
5-Day Change +4.14 (+3.75%) +4.14 (+3.75%)
52-Week Range 105.18 - 157.98 105.18 - 157.98
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,583,611
  • Shares Outstanding, K 99,704
  • Annual Sales, $ 2,355 M
  • Annual Income, $ 341,300 K
  • EBIT $ 571 M
  • EBITDA $ 571 M
  • 60-Month Beta 0.35
  • Price/Sales 4.89
  • Price/Cash Flow 34.20
  • Price/Book 4.52

Options Overview Details

View History
  • Implied Volatility 32.67% ( +0.40%)
  • Historical Volatility 27.39%
  • IV Percentile 45%
  • IV Rank 14.41%
  • IV High 94.83% on 08/06/24
  • IV Low 22.21% on 05/16/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 17
  • Volume Avg (30-Day) 575
  • Put/Call OI Ratio 0.70
  • Today's Open Interest 15,203
  • Open Int (30-Day) 17,200

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.70
  • Number of Estimates 10
  • High Estimate 1.33
  • Low Estimate 0.11
  • Prior Year 0.42
  • Growth Rate Est. (year over year) +66.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
105.18 +8.82%
on 03/11/25
Period Open: 117.59
119.00 -3.82%
on 03/03/25
-3.14 (-2.67%)
since 02/26/25
3-Month
105.18 +8.82%
on 03/11/25
Period Open: 139.03
154.61 -25.98%
on 01/30/25
-24.58 (-17.68%)
since 12/26/24
52-Week
105.18 +8.82%
on 03/11/25
Period Open: 141.16
157.98 -27.55%
on 08/01/24
-26.71 (-18.92%)
since 03/26/24

Most Recent Stories

More News
Neurocrine Biosciences: A Smart Biotech Bet With Blockbuster Potential

Explore the exciting world of Neurocrine Biosciences (NASDAQ: NBIX) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends...

NVDA : 113.76 (-5.74%)
NBIX : 114.45 (-1.49%)
Why Neurocrine Biosciences Stock Sank Today

Despite better-than-expected profitability in the fourth quarter, which it reported late last week, Neurocrine Biosciences (NASDAQ: NBIX) hasn't been wowing analysts lately. On Monday, no less than three...

NBIX : 114.45 (-1.49%)
UBS : 33.21 (-1.37%)
Neurocrine Biosciences Reports Mixed Q4

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates.

NBIX : 114.45 (-1.49%)
TEVA : 15.69 (-0.06%)
Neurocrine: Q4 Earnings Snapshot

Neurocrine: Q4 Earnings Snapshot

NBIX : 114.45 (-1.49%)
Neurocrine: Q3 Earnings Snapshot

Neurocrine: Q3 Earnings Snapshot

NBIX : 114.45 (-1.49%)
Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options

Investors in Neurocrine Biosciences, Inc. NBIX need to pay close attention to the stock based on moves in the options market lately. That is because the Nov. 15, 2024 $80.00 Call had some of the highest...

NBIX : 114.45 (-1.49%)
"Rule Breaker Investing" Market Cap Game Show: Throwdowns & Long-Term Wins

Motley Fool analysts Matt Argersinger and Yasser El-Shimy face off.

MSFT : 389.97 (-1.31%)
SHOP : 104.28 (-5.04%)
LOW : 232.05 (+0.59%)
TDG : 1,394.04 (-0.01%)
NBIX : 114.45 (-1.49%)
AMD : 110.19 (-4.02%)
RKLB : 19.44 (-4.09%)
SONO : 11.45 (-1.46%)
HEI : 268.83 (-0.75%)
SYNA : 64.35 (-1.39%)
KFRC : 48.87 (+0.64%)
3 Top Growth Stocks to Buy at a Discount This Month

According to analysts, here are three top-notch mid-cap growth stocks to snag at a discount now.

$IDX : 2,991.10 (-0.61%)
NBIX : 114.45 (-1.49%)
FLR : 37.74 (-2.58%)
$SPX : 5,712.20 (-1.12%)
SON : 47.13 (+1.55%)
Why Neurocrine Biosciences Stock Was Tumbling This Week

The company promises to advance a top investigational drug to late-stage testing, but investors might not think that's a fine idea.

NBIX : 114.45 (-1.49%)
New Study Reveals How Classical Music Could Revolutionize Depression Care

In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of patients...

ALZN : 1.0000 (-0.99%)
NBIX : 114.45 (-1.49%)
TAK : 15.02 (-0.13%)
AXSM : 119.16 (-1.00%)
BIIB : 142.43 (+2.35%)
Neurocrine: Q2 Earnings Snapshot

Neurocrine: Q2 Earnings Snapshot

NBIX : 114.45 (-1.49%)
Neurocrine: Q1 Earnings Snapshot

Neurocrine: Q1 Earnings Snapshot

NBIX : 114.45 (-1.49%)
Neurocrine: Q4 Earnings Snapshot

Neurocrine: Q4 Earnings Snapshot

NBIX : 114.45 (-1.49%)
Neurocrine: Q3 Earnings Snapshot

Neurocrine: Q3 Earnings Snapshot

NBIX : 114.45 (-1.49%)
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2023 Financial Results

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2023 financial results conference call and...

NBIX : 114.45 (-1.49%)
Neurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints

CAHtalyst™ Pediatric Study Met Primary Endpoint Demonstrating a Statistically Significant Decrease from Baseline in Serum Androstenedione in Children and...

NBIX : 114.45 (-1.49%)
Neurocrine Biosciences Presents Post Hoc Data Analysis in Congenital Adrenal Hyperplasia at ESPE 2023

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced that it will present a new post hoc analysis of Phase 2 data of the...

NBIX : 114.45 (-1.49%)
Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA® (valbenazine) Oral Granules Sprinkle Formulation

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application...

NBIX : 114.45 (-1.49%)
Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH)

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced positive top-line data from the Phase 3 CAHtalyst™ Adult Study evaluating the...

NBIX : 114.45 (-1.49%)
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the...

NBIX : 114.45 (-1.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding...

See More

Key Turning Points

3rd Resistance Point 119.28
2nd Resistance Point 117.76
1st Resistance Point 116.10
Last Price 114.45
1st Support Level 112.92
2nd Support Level 111.40
3rd Support Level 109.74

See More

52-Week High 157.98
Fibonacci 61.8% 137.81
Fibonacci 50% 131.58
Fibonacci 38.2% 125.35
Last Price 114.45
52-Week Low 105.18

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies